Biotech Values

[DewDiligence]

RNAI remark on HCV program:

Who thinks this is hype, and who thinks is isn’t? Please state you reasons. T.i.a.

“RNAi technology for antiviral applications is unique in that, unlike small-molecule-based drug development, we can readily produce multiple siRNA’s against a viral target, thus greatly reducing the virus’s ability to develop resistance by mutation.”
—Howard Robin, RNAI CEO, on Monday’s CC